Overview

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Status:
Completed
Trial end date:
2019-04-11
Target enrollment:
Participant gender:
Summary
Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and geographically diverse population could best be accomplished by the established infrastructure of the Global Network for Women's and Children's Health Research (GN).
Phase:
N/A
Details
Lead Sponsor:
NICHD Global Network for Women's and Children's Health
Collaborators:
Jawaharlal Nehru Medical College
KLE University's Jawaharlal Nehru Medical College
Thomas Jefferson University
Treatments:
Aspirin